linjc16/ctgov huggingface dataset:
Non-Invasive Optical Spectroscopic Methods for Dehydration Identification in Marathon Trainees

Study Overview
=================
Brief Summary
-----------------
Dehydration can result from exposure to harsh environments including hot and dry desert climates. Soldiers and non-military workers are frequently required to work in hot, dry conditions, and dehydration can be productivity limiting and life threatening if unrecognized.

Detailed Description
-----------------
The research can use low power laser technology to take measurements of muscle tissue water content in volunteers before and after marathon training runs to detect dehydration. Two slightly different devices can be used to detect dehydration. 1). diffuse optical spectroscopy and 2). spatial frequency domain imaging-modulated imaging The researchers can determined by use other methods to assess the level of dehydration status in runners. These methods will include taking weight and temperature before and after run, skin-fold measurements pre and post run, and obtaining saliva samples from before and after run. The researchers can determine the study use non-invasive, laser light technology measure tissue water concentrations, as an indicator of dehydration.

Official Title
-----------------
Non-Invasive Optical Spectroscopic Methods for Dehydration Identification in Marathon Trainees

Conditions
-----------------
Dehydration

Intervention / Treatment
-----------------
* Device: Non-Invasive Optical Spectroscopic


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male female ages of 18 and 60 training for a marathon Exclusion Criteria: Poorly controlled diabetes mellitus Diabetes insipidus (excessive urination of water) as diagnosed by your physician disorder of the intestine Irritable bowel syndrome with excessive diarrhea, as diagnosed by a physician Congestive heart failure and subsequent use of a diuretic water pill to remove excess water from the body Have poor kidney function Have been diagnosed with hyperthyroidism/hypothyroidism by your physician

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Dehydration<br>Non-Invasive Optical Spectroscopic monitoring method for dehydration | Device: Non-Invasive Optical Spectroscopic<br>* Non-Invasive Optical Spectroscopic<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hydration | Marathon Trainees | up to 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dehydration
Acute Myocardial Infarction Study in Northeastern China

Study Overview
=================
Brief Summary
-----------------
This is a real-world prospective cohort study aiming to generate knowledge about the characteristics, treatments, and outcomes of hospitalized AMI patients in Jilin Province. The study includes hospitalizations diagnosed of AMI, including ST segment-elevation myocardial infarction (STEMI) and non-ST-segment-elevation myocardial infarction (NSTEMI).

Official Title
-----------------
the Acute Myocardial Infarction Study in Northeastern China

Conditions
-----------------
Acute Myocardial Infarction

Intervention / Treatment
-----------------
* Procedure: thrombolysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients admitted within 7 days of acute myocardial ischemic symptoms with a primary clinical diagnosis of AMI, meet Fourth Universal Definition for Myocardial Infarction (2018) Exclusion Criteria: Types 4a and type 5 AMI
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Transfer after thrombolysis<br> | Procedure: thrombolysis<br>* transfer after thrombolysis for STEMI patients within 6h since onset<br>* Other names: DAPT;|
| Transfer after DAPT<br> | |
| Direct transfer<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all-cause death | all-cause death | 2 years post discharge | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| major adverse cardiac events (MACE) | recurrent angina, non-fatal myocardial infarction, cardiac failure, malignant arrhythmia, and death from cardiovascular causes | 2 years post discharge |
Prediction of Early Pre-eclampsia From Maternal Factors, Biophysical and Biochemical Markers at First Trimester

Study Overview
=================
Brief Summary
-----------------
The aims of this study are to develop algorithms based on a combination of maternal factors, uterine artery PI, MAP and serum biomarkers to estimate patient-specific risks for early Preeclampsia (PE) and to evaluate the screening performance of such algorithms in twins.

Detailed Description
-----------------
Preeclampsia (PE) is still a leading cause of fetal and maternal morbidity and mortality with an incidence of 3-5% worldwide. Despite intensive research efforts the pathogenesis of the disease is still unknown but it is likely to be multifactorial.Clinical risk factors traditionally have been used to identify women at high risk of developing preeclampsia,and biophysical factors that may help predict hypertensive disorders of pregnancy.In addition,changes in the serum concentrations of angiogenic and antiangiogenic factors are implied in the pathogenesis of PE and have possible relevance in the diagnosis of the disease.

Official Title
-----------------
Prediction of Early Pre-eclampsia From Maternal Factors, Biophysical and Biochemical Markers at First Trimester

Conditions
-----------------
Pre-Eclampsia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: twins pregnancies delivering a phenotypically normal stillbirth or live birth at or after 24 weeks of gestation. twins pregnancies at at 11-14 weeks of gestation Exclusion Criteria: pregnancies with major fetal abnormalities and those ending in termination, miscarriage or fetal death before 24 weeks

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| observational women<br>collecting maternal factors, biophysical and biochemical markers at 11-13 weeks of gestation. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Early preeclampsia |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Selective intrauterine fetal growth restriction |  | 1 year |
African-American Heart Failure Trial

Study Overview
=================
Brief Summary
-----------------
A placebo-controlled trial of BiDil added to standard therapy in African-American patients with heart failure.

Detailed Description
-----------------
The overall objective is confirmation of BiDil's Safety and Efficacy in African-American (AFA) Patients with Moderate to Severe Symptomatic Heart Failure.

Conditions
-----------------
Congestive Heart Failure

Intervention / Treatment
-----------------
* Drug: BiDil


Participation Criteria
=================
Eligibility Criteria
-----------------
African American male or female 18 years or older. NYHA Class 3 & 4. Have either a resting LVEF less than or equal to 35% (by any method) or a resting LVIDD greater than 2.9 cm/m2 BSA (or greater than 6.5 cm) with LVEF less than 45% (by echocardiogram).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: BiDil|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Relation Between Withdrawal Movement for Rocuronium and Emergence Agitation

Study Overview
=================
Brief Summary
-----------------
Rocuronium results in burning pain on injection site. It can be reduced by local anesthetics or opioid, but still some patients, especially in children, show withdrawal movement for pain. This might resulted from individual pain sensitivity. Emergence agitation (EA) in children is quite frequent postoperatively and is known to be associated with postoperative pain. If a patient is susceptible to postoperative pain, he or she would have high probability of EA postoperatively. Therefore, the investigators explore the relation of withdrawal movement of rocuronium and EA.

Official Title
-----------------
Relation Between Withdrawal Movement on Rocuronium Injection and Emergence Agitation and Pain in Preschool Ages: Observational Study

Conditions
-----------------
Inguinal Hernia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA class I, II Exclusion Criteria: Intravenous cannulation other than a hand or an upper arm with 24 gauge catheter

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 5 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No pain<br>patients show no pain on rocuronium injection | |
| mild pain<br>patients move a hand only on rocuronium injection | |
| moderate pain<br>patients move a arm on rocuronium injection | |
| severe pain<br>patients show generalized movement because of pain | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| emergence agitation (Watcha scale) | Watcha scale | 1 min after postanesthesia care unit (PACU) admission | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain (FLACC scale) | FLACC scale (Face, Leg, Activity, Cry, Consolability) | 1. 1 min after postanesthesia care unit (PACU) admission 2. 10 min after PACU admission 3. 20 min after PACU admission 4. 30 min after PACU admission 5. 40 min after PACU admission | 
| emergence agitation (Watcha scale) |  | 2. 10 min after PACU admission 3. 20 min after PACU admission 4. 30 min after PACU admission 5. 40 min after PACU admission |
Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the effect of bifeprunox or risperidone on the body weight of patients with schizophrenia.

Official Title
-----------------
A Multicenter, Randomized, Double-blind, Parallel-group Fixed-dose Study of the Effect on Weight of Bifeprunox Versus Risperidone in the Treatment of Outpatients With Schizophrenia.

Conditions
-----------------
Schizophrenia

Intervention / Treatment
-----------------
* Drug: bifeprunox
* Drug: risperidone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Current treatment of at least 3 months with risperidone. Primary diagnosis of schizophrenia. Total Positive and Negative Symptoms Scale (PANSS) score < or = 70 at screening and baseline. Exclusion criteria: Psychiatric diagnosis other than schizophrenia as assessed by the modified Mini International Neuropsychiatric Interview (MINI) and considered by the investigator to be the primary psychiatric diagnosis. History or presence of clinically significant cardiovascular, endocrine, hepatic, renal or other medical disease that might be detrimental to the subject or confound the study. History of any suicide attempt within 3 years of day 1 or significant immediate risk of violence or suicidality.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br> | Drug: bifeprunox<br>* .25mg titrate up to 20mg/day (week 1) then 30mg/day (weeks 2-8)<br>|
| Active Comparator: B<br> | Drug: risperidone<br>* 4mg, QD, 8 week treatment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary analysis will be the change from baseline on body weight at the final evaluation. |  | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Secondary outcomes include: Change from baseline in triglyceride level, Change from baseline in waist circumference, and Change from baseline in total Positive and Negative Syndrome Scale (PANSS) score. |  | 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Schizophrenia
PROGENI (Parkinson's Research: The Organized Genetics Initiative) Family Study of LRRK2 (Leucine-rich Repeat Kinase 2)

Study Overview
=================
Brief Summary
-----------------
The PROGENI Family Study is part of a larger consortium that is studying a gene shown to be important in Parkinson's disease, called LRRK2. People who have a defect in the LRRK2 gene will often develop Parkinson's disease. Eligible participants will be asked to complete a single Study Visit at an affiliated research facility closest to their home.

Detailed Description
-----------------
Participants will be asked to complete a family history questionnaire, which will gather information about their family history of Parkinson's disease and related disorders. They will be asked to complete a single Study Visit, during which they will be asked to do some or all of the following: Complete questionnaires regarding Parkinson's disease symptoms, medical history, mood, sleep, mental status, and activity level. Be given a brief standard neurological examination. Be given a scratch and sniff smell identification test. Be asked to give a sample of approximately 2 tablespoons of blood. Be asked to give a urine sample of approximately 1 tablespoon of urine.

Official Title
-----------------
PROGENI (Parkinson's Research: The Organized Genetics Initiative) Family Study

Conditions
-----------------
Parkinson Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Positive for a LRRK2 mutation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Observation and biological specimen collection |  | 1 time | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Parkinson disease, Parkinson's Disease, PD, LRRK2, genetics, genes
Effectiveness of Probiotic Supplementation on Crying Time in Infantile Colic

Study Overview
=================
Brief Summary
-----------------
This study aims to investigate the effectiveness of Lactobacillus reuteri DSM17938 supplementation on infantile colic in Indonesian infants.

Detailed Description
-----------------
Infantile colic is a problem faced by many parents and caregivers. There is no evidence that medications does help in this situation. The etiology of infantile colic is still unknown. Lactobacillus reuteri has been shown in five studies to reduce crying time in infants diagnosed with infantile colic.

Official Title
-----------------
Effectiveness of Lactobacillus Reuteri DSM17938 Supplementation on Crying Time in Infantile Colic

Conditions
-----------------
Colic, Infantile

Intervention / Treatment
-----------------
* Dietary Supplement: Lactobacillus reuteri DSM17938
* Dietary Supplement: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: otherwise healthy infants Infantile colic according to Roe IV criteria Full term infants Birth weight 2500 - 4000g Exclusively breast milk or partially breastfed Mothers last education degree is Senior high school Exclusion Criteria Clinically suspected allergy Consumption of probiotics, antibiotics, PPI Failure to thrive

Ages Eligible for Study
-----------------
Maximum Age: 3 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Lactobacillus reuteri DSM17938<br>Oil drops | Dietary Supplement: Lactobacillus reuteri DSM17938<br>* 5 drops of active oil drops. The active dose consists of 10^8 CFU L retueri DSM17938<br>|
| Placebo Comparator: Placebo<br>Oils drops | Dietary Supplement: Placebo<br>* 5 drops of placebo drops<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Daily average of crying time with L reuteri vs placebo | Daily crying diary | day 7 | 
| Daily average of crying time with L reuteri vs placebo | Daily crying diary | Day 14 | 
| Daily average of crying time with L reuteri vs placebo | Daily crying diary | Day 21 | 
| Daily average of crying time with L reuteri vs placebo | Daily crying diary | Day 28 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of responder vs non-responders | Daily crying | baseline, day 7, 14, 21, 28 | 
| Reduction of daily average crying time | Daily crying | baseline, day 7, 14, 21, 28 | 
| Parents perception of colic severity (Diary) | Diary | baseline, day 7, 14, 21, 28 | 
| Parents/Family quality of life (Diary) | Diary | baseline, day 7, 14, 21, 28 | 
| Parental satisfactory (Diary) | Diary | baseline, day 7, 14, 21, 28 |
Assessment of the Efficacy of Tracheal Oxygen Administration During Bronchoscopy - a Phase II Trial

Study Overview
=================
Brief Summary
-----------------
The aim of the present study is to measure the time to correction of O2 saturation when in case of desaturation below 90%, O2 administration is switched from the nasal to the tracheal route at a similar flow rate.

Detailed Description
-----------------
The development of a flexible bronchoscope with a channel dedicated to O2 administration might allow optimization of the oxygen supplementation during bronchoscopy, which reduces the risk of per- and peri-procedural hypoxemia. The investigators will conduct a pilot study corroborating the hypothesis that tracheal supplementation of oxygen during flexible bronchoscopy is advantageous in comparison to nasal cannula supplementation. The concept of our trial consists of a mono-centric observational study performed in the endoscopy suite of the Respiratory Division, University Hospitals Leuven. All patients will be given informed consent before inclusion. The aim of the present study is to measure the time to correction of O2 saturation when in case of desaturation below 90%, O2 administration is switched from the nasal to the tracheal route at a similar flow rate.

Official Title
-----------------
Assessment of the Efficacy of Tracheal Oxygen Administration During Bronchoscopy - a Phase II Trial.

Conditions
-----------------
Hypoxaemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients referred for flexible bronchoscopy Exclusion Criteria: broncho-alveolar lavage endobronchial plugging
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| conscious<br>bronchoscopy without sedative drugs | |
| conscious sedation<br>bronchoscopy under midazolam | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to correction of SpO2 |  | procedure |
Effect of LANCONONE in Weight-bearing Joint Pain

Study Overview
=================
Brief Summary
-----------------
The current study has been designed to primarily assess the effect of Lanconone® in comparison to placebo on pain in weight bearing joints.

Official Title
-----------------
To Assess the Lanconone® (E-OA-07) Efficacy in Weight-bearing Joint Pain

Conditions
-----------------
Osteo Arthritis Knee

Intervention / Treatment
-----------------
* Dietary Supplement: Lanconone®
* Dietary Supplement: Methyl crystalline cellulose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI ≥ 25 and ≤ 29.9 kg/m2. With unilateral or bilateral OA of the knee for at least greater than 3 months, as presented by pain in the knee at least for last 3 months. Post-menopausal females (LMP at least 12 months prior to the screening). Exclusion Criteria: History of osteoarthritis for more than 3 years. Systolic Blood Pressure ≥140 mm Hg and Diastolic Blood Pressure ≥ 90 mm Hg FBS>140 mg/dl. Smokers or chronic alcoholics. Participants planning to travel in the next 56 days or engage in any non-routine activity that is likely to strain the knees.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Lanconone®<br>Lanconone®: 2 Capsules once a day after breakfast | Dietary Supplement: Lanconone®<br>* 2 capsules<br>|
| Placebo Comparator: Methyl Crystalline Cellulose<br>2 Capsules once a day after breakfast | Dietary Supplement: Methyl crystalline cellulose<br>* 2 Capsules<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| WOMAC (Western Ontario and McMaster universities Osteoarthritis Index) pain score | Change in pain score.The score ranges from 0-5, wherein 0 indicates no pain and 5 indicates extreme pain. | 56 days |